AR015418A1 - Procedimiento para la preparacion de la forma cristalina (modificacion 1) de la n-(trifluormetil-fenil)-5-metil-isoxazol-4-carboxamida. - Google Patents

Procedimiento para la preparacion de la forma cristalina (modificacion 1) de la n-(trifluormetil-fenil)-5-metil-isoxazol-4-carboxamida.

Info

Publication number
AR015418A1
AR015418A1 ARP980103900A ARP980103900A AR015418A1 AR 015418 A1 AR015418 A1 AR 015418A1 AR P980103900 A ARP980103900 A AR P980103900A AR P980103900 A ARP980103900 A AR P980103900A AR 015418 A1 AR015418 A1 AR 015418A1
Authority
AR
Argentina
Prior art keywords
preparation
isoxazol
carboxamide
phenyl
methyl
Prior art date
Application number
ARP980103900A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR015418A1 publication Critical patent/AR015418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP980103900A 1997-08-08 1998-08-06 Procedimiento para la preparacion de la forma cristalina (modificacion 1) de la n-(trifluormetil-fenil)-5-metil-isoxazol-4-carboxamida. AR015418A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
AR015418A1 true AR015418A1 (es) 2001-05-02

Family

ID=26038983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103900A AR015418A1 (es) 1997-08-08 1998-08-06 Procedimiento para la preparacion de la forma cristalina (modificacion 1) de la n-(trifluormetil-fenil)-5-metil-isoxazol-4-carboxamida.

Country Status (28)

Country Link
US (5) US6060494A (https=)
EP (2) EP0903345B1 (https=)
JP (2) JPH11124372A (https=)
KR (2) KR100544041B1 (https=)
CN (2) CN1181064C (https=)
AR (1) AR015418A1 (https=)
AT (2) ATE196764T1 (https=)
AU (1) AU752764B2 (https=)
BR (1) BR9806568A (https=)
CA (1) CA2245267C (https=)
CZ (3) CZ301514B6 (https=)
DE (2) DE59800287D1 (https=)
DK (2) DK0987256T3 (https=)
ES (2) ES2150808T3 (https=)
GR (1) GR3034814T3 (https=)
HK (1) HK1049481B (https=)
HU (2) HU225870B1 (https=)
ID (1) ID20667A (https=)
IL (1) IL125671A (https=)
NO (1) NO310871B1 (https=)
NZ (1) NZ331270A (https=)
PL (1) PL192126B1 (https=)
PT (2) PT903345E (https=)
RU (1) RU2224753C2 (https=)
SK (2) SK282641B6 (https=)
TR (2) TR199801513A3 (https=)
TW (1) TW593288B (https=)
UA (1) UA54411C2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
EP1340749A4 (en) * 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2003068239A1 (en) * 2002-02-12 2003-08-21 Sumitomo Pharmaceuticals Co., Ltd. Novel drugs for external use
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
EA017064B1 (ru) * 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
NZ598744A (en) 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
ES2102367T3 (es) * 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
GB9115377D0 (en) * 1991-07-17 1991-09-04 Rhone Poulenc Agriculture New compositions of matter
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
TW314467B (https=) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
ATE194912T1 (de) * 1994-10-17 2000-08-15 Aventis Pharma Ltd Mittel zur vorsorge und heilung von typ i allergischen krankheiten
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
HUP9801844A2 (hu) 2000-02-28
ATE207065T1 (de) 2001-11-15
AU752764B2 (en) 2002-09-26
KR100544041B1 (ko) 2006-09-18
ATE196764T1 (de) 2000-10-15
EP0987256A1 (de) 2000-03-22
DK0987256T3 (da) 2002-02-11
US6995272B2 (en) 2006-02-07
TW593288B (en) 2004-06-21
RU2224753C2 (ru) 2004-02-27
AU7887098A (en) 1999-02-18
CN1181064C (zh) 2004-12-22
NO310871B1 (no) 2001-09-10
DK0903345T3 (da) 2000-10-23
HUP9801844A3 (en) 2000-04-28
CZ246898A3 (cs) 1999-02-17
EP0987256B1 (de) 2001-10-17
TR200600582A1 (tr) 2006-08-21
CZ292943B6 (cs) 2004-01-14
US6552202B2 (en) 2003-04-22
US6221891B1 (en) 2001-04-24
DE59800287D1 (de) 2000-11-09
NO983632D0 (no) 1998-08-07
HK1017681A1 (en) 1999-11-26
IL125671A (en) 2002-11-10
EP0903345A1 (de) 1999-03-24
CZ301514B6 (cs) 2010-03-31
US6060494A (en) 2000-05-09
US20030027851A1 (en) 2003-02-06
PT987256E (pt) 2002-03-28
SK285216B6 (sk) 2006-09-07
EP0903345B1 (de) 2000-10-04
CA2245267A1 (en) 1999-02-08
KR100588254B1 (ko) 2006-06-12
CN1089759C (zh) 2002-08-28
HK1049481A1 (en) 2003-05-16
GR3034814T3 (en) 2001-02-28
CA2245267C (en) 2008-12-23
JPH11124372A (ja) 1999-05-11
CN1373126A (zh) 2002-10-09
TR199801513A2 (xx) 1999-02-22
HK1049481B (zh) 2005-07-08
HU229232B1 (en) 2013-09-30
US20030166945A1 (en) 2003-09-04
NO983632L (no) 1999-02-09
ES2150808T3 (es) 2000-12-01
JP2009280604A (ja) 2009-12-03
CN1208034A (zh) 1999-02-17
KR19990023433A (ko) 1999-03-25
US6900334B2 (en) 2005-05-31
PT903345E (pt) 2001-01-31
UA54411C2 (uk) 2003-03-17
HU225870B1 (en) 2007-11-28
TR199801513A3 (tr) 1999-02-22
SK105898A3 (en) 1999-02-11
PL327901A1 (en) 1999-02-15
BR9806568A (pt) 2000-05-16
HU9801844D0 (en) 1998-10-28
ES2166205T3 (es) 2002-04-01
DE59801792D1 (de) 2001-11-22
ID20667A (id) 1999-02-11
KR20050077498A (ko) 2005-08-02
PL192126B1 (pl) 2006-09-29
SK282641B6 (sk) 2002-10-08
HU0700190D0 (en) 2007-05-02
IL125671A0 (en) 1999-04-11
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
CZ301426B6 (cs) 2010-02-24

Similar Documents

Publication Publication Date Title
AR015418A1 (es) Procedimiento para la preparacion de la forma cristalina (modificacion 1) de la n-(trifluormetil-fenil)-5-metil-isoxazol-4-carboxamida.
MX9202580A (es) Mascara quirurgica para los ojos.
BR9402558A (pt) Compostos, processo para sua preparação, composições farmacêuticas e uso dos compostos
PT91158A (pt) Processo para a preparacao de novos estirenos e carboxamidas heterociclicos biciclicos e composicoes farmaceuticas que os contem
DE59300192D1 (de) Chirurgisches Nahtmaterial.
ES2135356B1 (es) Peliculas mejoradas de mantillo agricola y metodos para su uso.
NO962286L (no) N-substituerte azabicykloalkanderivater som neuroleptika etc.
ES2063097T3 (es) Inhibidor de la glicosidasa salbostatina, procedimiento para su preparacion y su empleo.
BR9100517A (pt) Derivados de 3-aril-pirrolidino-2,4-diona,processo para sua preparacao,composicao inseticida,acaricida e herbicida,processo para preparacao de composicoes inseticidas
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
ES2097297T3 (es) Isoquinolein-5-il-sulfonamidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
PT952974E (pt) Derivados bifenilicos substituidos por um radical aromatico ou heteroaromatico e composicoes farmaceuticas e cosmeticas que os contem
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
DE69406468D1 (de) Mesomorphe Verbindung, Flüssigkristallzusammensetzung und Flüssigkristallvorrichtung
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
DE69114730D1 (de) Flüssigkristallverbindung.
BR8106480A (pt) Composicoes herbicidas a base de derivados de 4h-3,1-benzoxazina e processo para a preparacao dos mesmos
DE69317512D1 (de) Flüssigkristallverbindung, Zusammensetzung und Vorrichtung
DE69406840D1 (de) Ferroelektrische Flüssigkristallmischung, sowie diese verwendende Flüssigkristallvorrichtung
ES2039211T3 (es) Nuevos n-glicosilamidoderivados, procedimientos para su obtencion y su empleo como medicamentos.
BR8003062A (pt) Benzoxazolil-estilbenos, processo para sua preparacao e processo para o aclaramento otico de materiais
DE59409923D1 (de) Substituierte aminoalkylaminopyridine
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas

Legal Events

Date Code Title Description
FG Grant, registration